Peptide stapling is am ethod for designing macrocyclic alpha-helical inhibitors of protein-protein interactions. However,o btaining ac ell-active inhibitor can require significant optimization. We report anovel stapling technique based on ad ouble strain-promoted azide-alkyne reaction, and exploit its biocompatibility to accelerate the discovery of cellactive stapled peptides.Asaproof of concept, MDM2-binding peptides were stapled in parallel, directly in cell culture medium in 96-well plates,a nd simultaneously evaluated in ap 53 reporter assay. This in situ stapling/screening process gave an optimal candidate that showed improved proteolytic stability and nanomolar binding to MDM2 in subsequent biophysical assays. a-Helicity was confirmed by ac rystal structure of the MDM2-peptide complex. This work introduces in situ stapling as av ersatile biocompatible techniquew ith many other potential high-throughput biological applications.
Abstract: Peptide stapling is am ethod for designing macrocyclic alpha-helical inhibitors of protein-protein interactions. However,o btaining ac ell-active inhibitor can require significant optimization. We report anovel stapling technique based on ad ouble strain-promoted azide-alkyne reaction, and exploit its biocompatibility to accelerate the discovery of cellactive stapled peptides.Asaproof of concept, MDM2-binding peptides were stapled in parallel, directly in cell culture medium in 96-well plates,a nd simultaneously evaluated in ap 53 reporter assay. This in situ stapling/screening process gave an optimal candidate that showed improved proteolytic stability and nanomolar binding to MDM2 in subsequent biophysical assays. a-Helicity was confirmed by ac rystal structure of the MDM2-peptide complex. This work introduces in situ stapling as av ersatile biocompatible techniquew ith many other potential high-throughput biological applications.
Macrocyclization is an effective strategy for reinforcing peptides in stable secondary structures. [1] Whilst short peptides derived from proteins can lack aw ell-defined conformation when used in isolation, cyclisation can restore the native bioactive conformation and hence function of ap ep-tide.B ym imicking native binding motifs,c yclized peptides can competitively inhibit protein-protein interactions of clinical relevance,a nd they have received substantial attention as potential therapeutics. [1, 2] One of the most intensely studied targets is the oncogenic p53/MDM2 interaction, in which an N-terminal a-helix of the tumor suppressor p53 binds ah otspot on MDM2, an E3 ubiquitin ligase that downregulates p53 and is overexpressed in some cancers. [3, 4] Numerous peptide therapeutics have been developed to target this interaction, with some reaching as far as earlyphase clinical trials. [5] [6] [7] [8] [9] [10] Stapled peptides are an important subset of macrocyclic peptides specific to a-helices. [11] [12] [13] [14] [15] Stapling involves two amino acids with non-native side chains that can be covalently linked, producing ac yclized peptide that may display enhanced proteolytic stability,b inding affinity,a nd cellular uptake.W hilst the term "stapling" was originally coined by Verdine and Walensky for work on all-hydrocarbon linkers generated by metathesis (after Grubbs), [11, 12, 16] there is now great interest in alternative chemistries for side-chain crosslinking to give peptides with novel structures and biological properties.O fp articular note are modular two-component strategies,w here the staple linkage and peptide are separate moieties prior to cyclisation ( Figure 1 ). [14] We recently developed at wo-component stapling technique that makes use of double Cu-catalyzed azide-alkyne cycloaddition (CuAAC), [7, 17, 18] following related work by Bong [19] and other click systems. [20] [21] [22] Combining at wo-component approach with click chemistry enables easy access to peptides bearing different functional staples.Whilst we appended cellpermeabilizing motifs to the staple,o thers have used at wocomponent approach to create photoswitchable, [23] reversible, [24] and dynamic linkers. [25] When screening for an optimal inhibitor,s tapling reactions are typically carried out on many peptide variants.A practical bottleneck for two-component strategies is that, unlike hydrocarbon stapling,c yclisation is typically done in solution to avoid on-resin site isolation. [7, 23, 25] Hence,from the pure unstapled peptide,e xtra purification is needed after cyclisation to remove reagents/catalyst prior to assays ( Figure 1 ).
We decided to develop astapling technique that would be biocompatible and so simple to conduct that it could be done in parallel on al arge peptide library,e ven directly in the culture medium of ap rimary cell-based 96-well assay (Figure 1 ). This in situ approach would be faster than setting up ad edicated stapling reaction for each library variant, which is required in all current methods,a nd eliminates the extra purification step needed in other two-component strategies.
Inspired by the strain-promoted azide-alkyne cycloaddition reaction (Figure 2a ), [26, 27] we report ac atalyst-free double-click technique for parallel stapling in cell culture.
This in situ strategy is the first example of stapling in al ive biological context, since most techniques are incompatible owing to metal catalysis, [7, 19, 20] inert atmosphere or protecting groups, [28, 29] or thiols [30] [31] [32] [33] /amines [34] that might cross-react in biological systems.W hilst the oxime/hydrazone staples by Horne, [25] photocycloaddition staples by Lin, [35] and macrocyclic organo-peptide hybrids by Fasan have potential for in situ use, [10] we favored an on-dynamic system without UV irradiation or recombinant precursors.
Strained diyne 1 was prepared according to the method of Orita et al., [36] and atest reaction with Fmoc-Aha-OH 2 gave the expected bis(triazole) compounds 3 and 4 (Figure 2b and Figure S1 .4.1 in the Supporting Information). Stapling of p53derived diazidopeptide A (Figure 2c )w ith linker 1 in 1:1 H 2 O/tBuOH gave stapled peptide A1 in 60 %y ield (Figure 2c ;a ssigned as the anti regioisomer,s ee later crystallography on an analogous peptide). Minor byproducts of the same mass were observed. These may be stable alternative conformations of the syn form, with MD simulations suggesting the possibility of at least two extra non-interchanging conformations ( Figure S12.1.3 ). An excess of 1 did not affect the reaction, and comparable results were obtained when swapping tBuOH for MeOH, MeCN,orDMSO.Importantly, the reaction also proceeded in Dulbeccos Modified Eagles medium (DMEM) with fetal calf serum and 1% DMSO.
Thebinding affinity of A1 for MDM2 was 3.1 AE 0.4 nm by competitive fluorescence polarization (FP), [7] which is more potent than that of wild-type p53 [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] (820 AE 60 nm)a nd unstapled A (16 AE 1nm). Despite this encouraging in vitro result, up to 100 mm of A1 did not induce activation of p53 in an established T22 cell reporter assay, [9] which is in line with previous studies showing poor uptake of this sequence. [6, 7] To test our in situ approach, we investigated sequence variants B-E,which are based on the phage-derived peptides PMI/PDI and were previously investigated for hydrocarbon stapling (Figure 3a ). [5, 8, 9, 37 To determine which variant would induce greatest p53 activation upon stapling with 1,w e directly treated p53 reporter cells for the cell-based assay [9] in 96-well format with 0.5 mm 1 and 50 mm unstapled peptides A-E in DMEM. All five peptides were stapled in situ with similar yields (54-58 %). After 18 hincubation, p53 activation was observed for B-E,w hilst no activation was observed for A ( Figure 3a ). Cells treated with 1 or A-E only showed no p53 activation. From this in situ procedure,w ew ere rapidly able to rank peptide activity,finding that E stapled with 1 (E + 1)w as the most potent activator of p53.
We resynthesized and isolated stapled peptides A1-E1 to verify that the activity ranking from in situ stapling was consistent with standard testing of pure peptides. [7] Stapling in H 2 O/tBuOH proceeded with similar yield in each case,a nd the same activity ranking was observed for the purified peptides in the reporter assay,w ith E1 again inducing the greatest response (Figure 3b ). An F3A control for E1 was found to have no cellular activity ( Figure S11.2.1) . The response using pure peptides was greater than in the in situ procedure,potentially due to gradual product formation over 18 ha nd losses due to syn/anti byproducts.D espite these possible confounding factors,the reactivity of linker 1 was still sufficiently robust to rank peptide activity. Bottom:U nlike classicalo ne-componentstapling [15] and existing twocomponent strategies such as our CuAAC method, [7, 18] the in situ strategy combines stapling and the primary biologicala ssay in asingle step. Figure 2 . a) Strain-promoted azide-alkyne cycloaddition (SPAAC). [26] b) Test double SPAAC on Fmoc-Aha-OH.c )Double-SPAAC stapling of p53-derivedd iazidopeptide A.
Angewandte Chemie
Taking E1 forward, we obtained its crystal structure in complex with MDM2 (17-108, E69A/K70A; [38] Figure 4 ). The structure shows E1 in a-helical conformation, placing the binding triad (F3, W7, L10) in the correct orientation for engaging the MDM2 hotspot. Theb is(triazolyl) staple is found as the anti regioisomer and forms interactions with the protein, ap henomenon only previously seen with hydrocarbon-stapled peptides ( Figure S5.3.2 ). [5, [39] [40] [41] By FP, [7, 9] A1-E1 all showed potent affinity for MDM2 (Figure 5a ), thus exemplifying how in vitro binding does not always translate to cellular activity,o wing to other factors such as uptake.Acomparable binding affinity for E1 was obtained by isothermal calorimetry (12 AE 3nm, Figure S4.2.1 ).
Based on thermal shift in OCI/AML-2 lysate, [42, 43] both E1 and control Nutlin-3 show increased stabilization of MDM2 (Figure 5b ). Uptake of E1 was observed by confocal microscopy in T22 cells (Figure 5c ). E1 did not exhibit non-specific toxicity in an LDH leakage assay ( Figure S9.1.1) , and was not observed to aggregate in solution by gel filtration and UV/Vis spectroscopy ( Figures S10.1.1, S10.1.2) . Finally, E1 showed significantly improved proteolytic stability in achymotrypsin assay (Figure 5d ).
In conclusion, this work introduces an ew stapling technique with unique biocompatibility.L inker 1 was used for stapling in situ, leading to rapid selection of optimal candidate E1.Having established the chemistry,wenow pave the way for applying in situ stapling to new biological targets. Only five peptides were screened in this study,s ince wellcharacterized sequences were already available.F or new targets,more variants will be needed before finding apromising hit. Am ajor advantage of our method is the potential to Figure 3 . p53 activation in acellular reporter assay for a) in situ stapling with peptides A-E (50 mm)and linker 1 (0.5 mm), and b) prestapled peptides A1-E1.U nstapled peptide controls A-E were tested at 100 mm (also see Figure S2 .2.1). X = Orn(N 3 ), data reported as fold activation over 1% DMSO. A is ap53-derivedpeptide (K24R) we previously used, [7] C is based on phage peptide PMI, and [8, 9] B, D,and E are based on phage peptide PDI. [5, 37] staple these variants with different strained linkers,efficiently covering aw ider area of chemical space.F inally,d ifferent high-throughput assays can enable rapid evaluation of other properties,f or example,h igh-content analysis of peptide uptake/localization, whilst stapling biosynthetic diazidopeptides could lead to vast screening libraries.
